Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876624 | 0.97 | CCR6 (0.33) | CCR6NR1H2NR1H3 | |
| SCHEMBL5877305 | 0.94 | CCR6 (0.35) | CCR6 | |
| SCHEMBL5878049 | 0.91 | SMN1; SMN2 (0.34) | USP2MAPK1CCR6NOD2NOD1 | |
| SCHEMBL5876674 | 0.90 | USP2 (0.35) | USP2MAPK1CCR6NOD2NOD1 | |
| SCHEMBL5876342 | 0.90 | CCR6 (0.35) | CCR6 | |
| SCHEMBL5876198 | 0.90 | USP2 (0.37) | USP2MAPK1CCR6NOD2NOD1 | |
| SCHEMBL5876223 | 0.88 | SMN1; SMN2 (0.33) | USP2MAPK1CCR6NR1H2NR1H3 | |
| SCHEMBL5877420 | 0.87 | NR1H2 (0.32) | NR1H2NR1H3 | |
| SCHEMBL5876220 | 0.87 | NR1H2 (0.34) | USP2MAPK1CCR6NR1H2NR1H3 | |
| SCHEMBL5877652 | 0.87 | ACHE (0.34) | USP2MAPK1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | USP2 3250/4885MAPK1 2357/4885CCR6 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.